EGFR and cancer: Building from previous studies, miR-107 could suppress cancer progression in many ways, such as targeting oncogene eukaryotic translation initiation factors (eIFs); transforming growth factor beta receptor 2 (TGFβR2); epidermal growth factor receptor (EGFR); or attenuating AMPK-mTOR, NOTH2, and other pathways (Table 1).